@article{TogninalliSerenMengetal.2018,
  author    = {Togninalli, Matteo and Seren, {\"U}mit and Meng, Dazhe and Fitz, Joffrey and Nordborg, Magnus and Weigel, Detlef and Borgwardt, Karsten and Korte, Arthur and Grimm, Dominik G.},
  title     = {The AraGWAS Catalog: a curated and standardized Arabidopsis thaliana GWAS catalog},
  series = {Nucleic Acids Research},
  volume    = {46},
  journal   = {Nucleic Acids Research},
  number    = {D1},
  doi       = {10.1093/nar/gkx954},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-158727},
  pages     = {D1150-D1156},
  year      = {2018},
  abstract  = {The abundance of high-quality genotype and phenotype data for the model organism Arabidopsis thaliana enables scientists to study the genetic architecture of many complex traits at an unprecedented level of detail using genome-wide association studies (GWAS). GWAS have been a great success in A. thaliana and many SNP-trait associations have been published. With the AraGWAS Catalog (https://aragwas.1001genomes.org) we provide a publicly available, manually curated and standardized GWAS catalog for all publicly available phenotypes from the central A. thaliana phenotype repository, AraPheno. All GWAS have been recomputed on the latest imputed genotype release of the 1001 Genomes Consortium using a standardized GWAS pipeline to ensure comparability between results. The catalog includes currently 167 phenotypes and more than 222 000 SNP-trait associations with P < 10\(^{-4}\), of which 3887 are significantly associated using permutation-based thresholds. The AraGWAS Catalog can be accessed via a modern web-interface and provides various features to easily access, download and visualize the results and summary statistics across GWAS.},
  language  = {en}
}
@article{SteinMarufMuelleretal.2021,
  author    = {Stein, Kiera and Maruf, Abdullah Al and M{\"u}ller, Daniel J. and Bishop, Jeffrey R. and Bousman, Chad A.},
  title     = {Serotonin transporter genetic variation and antidepressant response and tolerability: a systematic review and meta-analysis},
  series = {Journal of Personalized Medicine},
  volume    = {11},
  journal   = {Journal of Personalized Medicine},
  number    = {12},
  issn      = {2075-4426},
  doi       = {10.3390/jpm11121334},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-252294},
  year      = {2021},
  abstract  = {Antidepressants are used to treat several psychiatric disorders; however, a large proportion of patients do not respond to their first antidepressant therapy and often experience adverse drug reactions (ADR). A common insertion-deletion polymorphism in the promoter region (5-HTTLPR) of the serotonin transporter (SLC6A4) gene has been frequently investigated for its association with antidepressant outcomes. Here, we performed a systematic review and meta-analysis to assess 5-HTTLPR associations with antidepressants: (1) response in psychiatric disorders other than major depressive disorder (MDD) and (2) tolerability across all psychiatric disorders. Literature searches were performed up to January 2021, yielding 82 studies that met inclusion criteria, and 16 of these studies were included in the meta-analyses. Carriers of the 5-HTTLPR LL or LS genotypes were more likely to respond to antidepressant therapy, compared to the SS carriers in the total and European ancestry-only study populations. Long (L) allele carriers taking selective serotonin reuptake inhibitors (SSRIs) reported fewer ADRs relative to short/short (SS) carriers. European L carriers taking SSRIs had lower ADR rates than S carriers. These results suggest the 5-HTTLPR polymorphism may serve as a marker for antidepressant outcomes in psychiatric disorders and may be particularly relevant to SSRI treatment among individuals of European descent.},
  language  = {en}
}
@article{SerenGrimmFitzetal.2016,
  author    = {Seren, {\"U}mit and Grimm, Dominik and Fitz, Joffrey and Weigel, Detlef and Nordborg, Magnus and Borgwardt, Karsten and Korte, Arthur},
  title     = {AraPheno: a public database for Arabidopsis thaliana phenotypes},
  series = {Nucleic Acids Research},
  volume    = {45},
  journal   = {Nucleic Acids Research},
  number    = {D1},
  doi       = {10.1093/nar/gkw986},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-147909},
  pages     = {D1054-D1059},
  year      = {2016},
  abstract  = {Natural genetic variation makes it possible to discover evolutionary changes that have been maintained in a population because they are advantageous. To understand genotype-phenotype relationships and to investigate trait architecture, the existence of both high-resolution genotypic and phenotypic data is necessary. Arabidopsis thaliana is a prime model for these purposes. This herb naturally occurs across much of the Eurasian continent and North America. Thus, it is exposed to a wide range of environmental factors and has been subject to natural selection under distinct conditions. Full genome sequencing data for more than 1000 different natural inbred lines are available, and this has encouraged the distributed generation of many types of phenotypic data. To leverage these data for meta analyses, AraPheno (https://arapheno.1001genomes.org) provide a central repository of population-scale phenotypes for A. thaliana inbred lines. AraPheno includes various features to easily access, download and visualize the phenotypic data. This will facilitate a comparative analysis of the many different types of phenotypic data, which is the base to further enhance our understanding of the genotype-phenotype map.},
  language  = {en}
}
@article{LendersWeidemannKurschatetal.2016,
  author    = {Lenders, Malte and Weidemann, Frank and Kurschat, Christine and Canaan-K{\"u}hl, Sima and Duning, Thomas and Stypmann, J{\"o}rg and Schmitz, Boris and Reiermann, Stefanie and Kr{\"a}mer, Johannes and Blaschke, Daniela and Wanner, Christoph and Brand, Stefan-Martin and Brand, Eva},
  title     = {Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant},
  series = {Orphanet Journal of Rare Diseases},
  volume    = {11},
  journal   = {Orphanet Journal of Rare Diseases},
  number    = {54},
  doi       = {10.1186/s13023-016-0441-z},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-166559},
  year      = {2016},
  abstract  = {Background Fabry disease (FD) is an X-linked multisystemic disorder with a heterogeneous phenotype. Especially atypical or late-onset type 2 phenotypes present a therapeutical dilemma. Methods To determine the clinical impact of the alpha-Galactosidase A (GLA) p.A143T/ c.427G > A variation, we retrospectively analyzed 25 p.A143T patients in comparison to 58 FD patients with other missense mutations. Results p.A143T patients suffering from stroke/ transient ischemic attacks had slightly decreased residual GLA activities, and/or increased lyso-Gb3 levels, suspecting FD. However, most male p.A143T patients presented with significant residual GLA activity (~50 \% of reference), which was associated with normal lyso-Gb3 levels. Additionally, p.A143T patients showed less severe FD-typical symptoms and absent FD-typical renal and cardiac involvement in comparison to FD patients with other missense mutations. Two tested female p.A143T patients with stroke/TIA did not show skewed X chromosome inactivation. No accumulation of neurologic events in family members of p.A143T patients with stroke/transient ischemic attacks was observed. Conclusions We conclude that GLA p.A143T seems to be most likely a neutral variant or a possible modifier instead of a disease-causing mutation. Therefore, we suggest that p.A143T patients with stroke/transient ischemic attacks of unknown etiology should be further evaluated, since the diagnosis of FD is not probable and subsequent ERT or chaperone treatment should not be an unreflected option.},
  language  = {en}
}
@phdthesis{Juling2010,
  author    = {Juling, Martin Johannes},
  title     = {Untersuchung der HBV-Genotypen bei antiviral behandelten Hepatitis B-Patienten im Zeitraum von 1997 bis 2004 an der Universit{\"a}tsklinik W{\"u}rzburg},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-48789},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2010},
  abstract  = {Von den acht bekannten HBV-Genotypen sind die Genotypen A und D in Europa vorherrschend, Genotyp A in Nordwesteuropa, Genotyp D im Mittelmeerraum und in S{\"u}dosteuropa. Dies best{\"a}tigte sich auch in der vorliegenden Studie, bei der von 62 genotypisierten Proben 91,9 \% diesen beiden Genotypen zugeordnet werden konnten. Genotyp D war mit 64,5 \% (40 Patienten) vorherrschend. Es folgten der Genotyp A (17 Patienten) und der Genotyp C (4 Patienten). In einem Fall wurde Genotyp B nachgewiesen. Deutschland als Herkunftsland war bei Patienten mit Genotyp A signifikant h{\"a}ufiger vertreten als bei Patienten mit Genotyp D. Der relativ hohe Genotyp D-Anteil ist m{\"o}glicherweise darauf zur{\"u}ckzuf{\"u}hren, dass durch zunehmende Immigration das Auftreten verschiedener Genotypen beispielsweise aus dem s{\"u}dosteurop{\"a}ischen Raum beg{\"u}nstigt wird. Patienten mit Genotyp A sprechen h{\"a}ufig besser auf IFN-alpha an, so dass eine Therapie mit Nukleosid- bzw. Nukleotidanaloga nicht erforderlich ist. Diese Patienten wurden somit {\`a} priori nicht in dieser Studie erfasst, was eine m{\"o}gliche Erkl{\"a}rung daf{\"u}r ist, dass der Genotyp A-Anteil mit 27,4 \% relativ gering ausfiel. Bei der Untersuchung von statistischen Zusammenh{\"a}ngen zwischen HBV-Genotyp und Patientenalter, Geschlecht, Viruslast und Therapiedauer ergaben sich keine signifikanten Ergebnisse. Diese Studie bietet Basisinformationen zur Genotypverteilung in Deutschland. Bez{\"u}glich einer Korrelation zwischen den verschiedenen HBV-Genotypen und demographischen, virologischen sowie klinischen Charakteristika wird es k{\"u}nftig weiterer Studien bed{\"u}rfen.},
  subject      = {Hepatitis B},
  language  = {de}
}